424B4 - Janus Living, Inc. (0002100805) (Filer)

EFFECT - Janus Living, Inc. (0002100805) (Filer)

S-11 - Janus Living, Inc. (0002100805) (Filer)

SCHEDULE 13G - Janus Living, Inc. (0002100805) (Subject)

10-Q - Janus Living, Inc. (0002100805) (Filer)

8-K - Janus Living, Inc. (0002100805) (Filer)

8-K - Janus Living, Inc. (0002100805) (Filer)

424B4 - Janus Living, Inc. (0002100805) (Filer)

S-8 - Janus Living, Inc. (0002100805) (Filer)

CERT - Janus Living, Inc. (0002100805) (Filer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

4 - Janus Living, Inc. (0002100805) (Issuer)

Scotiabank initiated coverage of Janus Living with a rating of Sector Outperform and set a new price target of $28.00

KeyBanc Capital Markets initiated coverage of Janus Living with a rating of Overweight and set a new price target of $28.00

Barclays initiated coverage of Janus Living with a rating of Overweight and set a new price target of $26.00

Morgan Stanley initiated coverage of Janus Living with a rating of Overweight and set a new price target of $28.00

Analyst initiated coverage of Janus Living with a rating of Overweight and set a new price target of $26.00

RBC Capital Mkts initiated coverage of Janus Living with a rating of Outperform and set a new price target of $27.00

Wells Fargo initiated coverage of Janus Living with a rating of Overweight and set a new price target of $27.00

BofA Securities initiated coverage of Janus Living with a rating of Buy and set a new price target of $29.00

BNP Paribas Exane initiated coverage of Janus Living with a rating of Outperform and set a new price target of $27.00

Goldman initiated coverage of Janus Living with a rating of Neutral and set a new price target of $27.00

Janus Living, Inc. (NYSE:JAN) ("Janus Living"), a pure-play senior housing real estate investment trust (REIT), announced today the pricing of its public offering of 25,000,000 shares of its Class A-1 common stock at a price to the public of $25.00 per share. In addition, Janus Living has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its Class A-1 common stock at the public offering price, less the underwriting discount. The offering is expected to close on June 4, 2026, subject to customary closing conditions. Janus Living expects to use the net proceeds received from the offering to pursue acquisition and investment opportunities that meet

Janus Living, Inc. (NYSE:JAN) ("Janus Living"), a pure-play senior housing real estate investment trust (REIT), announced today the launch of its public offering of 25,000,000 shares of its Class A-1 common stock pursuant to a registration statement on Form S-11 filed with the Securities and Exchange Commission (the "SEC"). Janus Living expects to grant the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its Class A-1 common stock. Janus Living expects to use the net proceeds received from the proposed offering to pursue acquisition and investment opportunities that meet its investment criteria and for general corporate purposes. BofA Securities, J.P. Mo

Janus Living, Inc. (NYSE:JAN), a pure-play senior housing real estate investment trust (REIT), announced its Board of Directors today declared a pro rata quarterly common stock cash dividend of $0.0174 per share for the first quarter of 2026 and a quarterly common stock cash dividend of $0.1425 per share for the second quarter of 2026, payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date in the table below. The quarterly dividend reflects an annualized dividend amount of $0.57 per share of common stock. Record Date Payment Date Amount Friday, June 12, 2026 Wednesday, Jun

Janus Living, Inc. (NYSE:JAN), a pure-play senior housing real estate investment trust (REIT), announced results for the quarter ended March 31, 2026. FIRST QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS (all percentage changes compare first quarter 2026 to first quarter 2025 unless otherwise noted) Post-IPO net loss of $(0.05) per share and quarterly net income of $0.13 per share Consolidated revenues of $200 million increased 35% and Adjusted EBITDAre of $65 million increased 42% FFO as Adjusted of $0.23 per share increased 35% Same-store adjusted NOI increased 13.8% and margin expanded 150 basis points ("bps") Same-store revenues increased 7.6% driven by 230 bps

Healthpeak Properties, Inc. (NYSE:DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended March 31, 2026. FIRST QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS Net income of $0.28 per share, Nareit FFO of $0.42 per share, and FFO as Adjusted of $0.45 per share In March 2026, Janus Living, Inc. (NYSE:JAN) ("Janus Living") completed its initial public offering ("IPO") at the high-end of the valuation range, generating approximately $880 million of net proceeds in an oversubscribed and upsized offering, to pursue accretive acquisition and investment opportunities As Janus Living's larg

Janus Living, Inc. (NYSE:JAN), a pure-play senior housing real estate investment trust (REIT), is scheduled to report first quarter 2026 financial results after the close of trading on the New York Stock Exchange on Tuesday, May 5, 2026. Janus Living will host a conference call and webcast on Wednesday, May 6, 2026 at 12:00 p.m. Eastern Time to review its financial performance and operating results. The conference call can be accessed in the following ways: Janus Living's website: https://ir.janusreit.com/events-and-presentations Webcast: https://events.q4inc.com/attendee/263858499. Joining via webcast is recommended for those who will not be asking questions. Telephone: The pa

Janus Living, Inc. (NYSE:JAN) ("Janus Living"), a pure-play senior housing real estate investment trust (REIT), announced today that it has closed on a new $500 million unsecured revolving credit facility (the "Revolving Facility") and a $100 million unsecured delayed-draw term loan facility (the "Term Loan", and together with the Revolving Facility, the "Credit Facility"). The Revolving Facility provides for borrowing up to $500 million and matures in March 2030, with two six-month extension options. The $100 million Term Loan includes a delayed-draw feature and matures in March 2031. Borrowings under the Revolving Facility and Term Loan bear interest at SOFR plus 105 and 110 basis poi

Healthpeak Properties, Inc. (NYSE:DOC) ("Healthpeak") and Janus Living, Inc. (NYSE:JAN) ("Janus Living") announced today that Janus Living has completed its initial public offering of 48,300,000 shares of its Class A-1 common stock, which includes the exercise in full by the underwriters of their option to purchase up to an additional 6,300,000 shares of Class A-1 common stock, at a price to the public of $20.00 per share. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323402409/en/ Shares of Janus Living's Class A-1 common stock began trading on the New York Stock Exchange on March 20, 2026 under the ticker symbol "JAN." T

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, March 20, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on March 20thMarkets are lower Friday morning after Israeli Prime Minister Benjamin Netanyahu said his country was assisting the U.S. in reopening the Strait of Hormuz.Janus Living (NYSE:JAN) will begin trading on the NYSE today and celebrates its IPO on-site this morning.Guardian Metal Resources CEO & Executive Director Olive

Healthpeak Properties, Inc. (NYSE:DOC) ("Healthpeak") and Janus Living, Inc. ("Janus Living") announced the pricing of Janus Living's upsized initial public offering ("IPO") of 42,000,000 shares of Janus Living Class A-1 common stock at a price to the public of $20.00 per share. In addition, Janus Living has granted the underwriters a 30-day option to purchase up to an additional 6,300,000 shares of its Class A-1 common stock at the initial public offering price, less the underwriting discount. Janus Living's Class A-1 common stock is expected to begin trading on the New York Stock Exchange on March 20, 2026 under the ticker symbol "JAN." The IPO is expected to close on March 23, 2026, subj

SC 13G/A - JanOne Inc. (0000862861) (Subject)

SC 13G - JanOne Inc. (0000862861) (Subject)

SC 13G/A - JanOne Inc. (0000862861) (Subject)

SC 13G/A - JanOne Inc. (0000862861) (Subject)

SC 13D - JanOne Inc. (0000862861) (Subject)

SC 13G - JanOne Inc. (0000862861) (Subject)

SC 13G - JanOne Inc. (0000862861) (Subject)

LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"

LAS VEGAS, June 26, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles in research, investment banking, and finance, notably and most recently as Managing Director and Head of Technology Investment Banking at PI Financial Corp. (Ventum Financial).

LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction.  Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby m

Janus Living, Inc. (NYSE:JAN), a pure-play senior housing real estate investment trust (REIT), announced its Board of Directors today declared a pro rata quarterly common stock cash dividend of $0.0174 per share for the first quarter of 2026 and a quarterly common stock cash dividend of $0.1425 per share for the second quarter of 2026, payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date in the table below. The quarterly dividend reflects an annualized dividend amount of $0.57 per share of common stock. Record Date Payment Date Amount Friday, June 12, 2026 Wednesday, Jun

Janus Living, Inc. (NYSE:JAN), a pure-play senior housing real estate investment trust (REIT), is scheduled to report first quarter 2026 financial results after the close of trading on the New York Stock Exchange on Tuesday, May 5, 2026. Janus Living will host a conference call and webcast on Wednesday, May 6, 2026 at 12:00 p.m. Eastern Time to review its financial performance and operating results. The conference call can be accessed in the following ways: Janus Living's website: https://ir.janusreit.com/events-and-presentations Webcast: https://events.q4inc.com/attendee/263858499. Joining via webcast is recommended for those who will not be asking questions. Telephone: The pa

-The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS, July 10, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisi

The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be i

LAS VEGAS, Dec. 7, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO).  The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides JanOne Inc. with an opportunity to identify new drugs to enhance TSPO activity, and by doing so, reducing craving for meth. This new strategy for treating MUD w